Skip to main content
Premium Trial:

Request an Annual Quote

German Researchers Using Affymetrix Tech for Liver Toxicity Dx

NEW YORK (GenomeWeb News) – Researchers at the Fraunhofer Institute in Germany are using Affymetrix’s Whole Transcript gene expression technology to develop a diagnostic test to detect drug-induced liver toxicity, the company said today.

Drug-induced liver toxicity is a common side effect of drug therapies and is “the most frequent reason why registered drugs are withdrawn from the market,” Affy said.

There is now “no reliable method to forecast the progression of various types of DILI,” and a tool that could be used to detect these could save around $2 billion per year in the US, Affy added.

The study is being led by professor Juergen Borlak, director of the Fraunhofer Institute of Toxicology and Experimental Medicine and head of the Institute of Pharmaco- and Toxicogenomics at the Hannover Medical School.

The Hannover Medical School is the largest liver transplant center in Europe, Affy said.

The company said the institute hopes to have a diagnostic tool ready for launch in the spring of 2009.

Financial terms of the agreement were not released.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.